Dilated Cardiomyopathy
A condition in which the heart's main pumping chamber becomes enlarged and weakened, reducing its ability to pump blood effectively.
Emergency Management: Acute decompensated heart failure with cardiogenic shock requires urgent ICU admission for IV inotropes (Dobutamine, Milrinone) or temporary mechanical circulatory support (e.g., IABP, Impella).
Dilated cardiomyopathy (DCM) is a primary myocardial disease characterized by left ventricular or biventricular dilation and impaired systolic function (ejection fraction < 45%), in the absence of coronary artery disease, hypertension, or valvular disease sufficient to explain the observed myocardial abnormality. It is the most common indication for heart transplantation.
Detailed Overview
DCM leads to progressive decline in ventricular contractile function. The compensatory mechanisms, including activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS), initially maintain cardiac output but eventually lead to maladaptive remodeling, worsening volume overload, and heart failure. The structural changes predispose the patient to life-threatening ventricular arrhythmias, conduction blocks, and mural thrombus formation.
Epidemiology & Demographics
Prevalence is estimated at 1 in 250 to 1 in 2,500 individuals. It occurs at any age but is most commonly diagnosed in the third to fourth decades of life. It is more prevalent and carries a worse prognosis in men and Black patients.
Etiological Mechanism
Approximately 20-35% of cases are familial, most commonly inherited in an autosomal dominant pattern with mutations in genes like TTN (titin). Secondary causes include viral myocarditis (Coxsackie B, Adenovirus), cardiotoxins (anthracyclines, chronic alcohol abuse, cocaine), metabolic disorders, and peripartum state.
Primary Causes
Genetic Mutations (e.g., TTN, LMNA, MYH7)
Viral Myocarditis
Alcohol/Substance Abuse
Chemotherapy Toxicity (e.g., Doxorubicin)
Idiopathic
The primary insult (genetic, infectious, or toxic) causes myocyte damage and necrosis. This triggers a reparative process leading to interstitial fibrosis and myocardial remodeling. The loss of functional myocytes results in decreased contractility. To compensate for reduced stroke volume, the ventricle dilates (eccentric hypertrophy). Wall stress increases according to Laplace's law, further increasing oxygen demand and neurohormonal activation, creating a vicious cycle of progressive systolic dysfunction and progressive chamber dilation.
Diagnostic Criteria & Guidelines
Diagnosis requires echocardiographic evidence of left ventricular enlargement (LVEDD > 117% of predicted value for age and body surface area) and systolic dysfunction (LVEF < 45% or fractional shortening < 25%). Ischemic etiology must be ruled out (usually via coronary angiography).
Guideline-directed medical therapy (GDMT) for HFrEF. 1. Beta-blockers (e.g., Carvedilol 3.125 mg BID titrated to 25 mg BID, or Metoprolol succinate). 2. ARNI (Sacubitril/Valsartan 24/26 mg BID titrated to 97/103 mg BID). 3. MRA (Spironolactone 12.5-25 mg daily). 4. SGLT2 Inhibitors (Dapagliflozin 10 mg daily). Diuretics (Furosemide 40 mg daily) for volume overload symptoms.
Second-Line & Adjunctive Therapy
Ivabradine (5 mg BID) if resting heart rate remains >70 bpm on max beta-blocker. Digoxin (0.125-0.25 mg daily) for symptomatic control in HFrEF with atrial fibrillation. Implantable Cardioverter Defibrillator (ICD) for primary prevention of SCD if LVEF remains <=35% despite 3 months of optimal GDMT.
Surgical & Procedural Management
Cardiac Resynchronization Therapy (CRT) if QRS > 150ms and LBBB morphology. Left Ventricular Assist Device (LVAD) as bridge to transplant or destination therapy for end-stage refactory HF. Orthotopic Heart Transplantation is the definitive surgical treatment.
Patient Counseling & Advice
Educate the patient to take daily morning weights and notify the clinician if weight increases by >2-3 lbs in 24 hours or 5 lbs in a week. Stress the critical importance of taking all HF medications exactly as prescribed, even if feeling well, to prevent disease progression.
Follow-Up & Monitoring Schedule
Echocardiogram every 3-6 months during titration of GDMT to assess for reverse remodeling. Renal function (creatinine, potassium) checked 1-2 weeks after initiating or titrating RAAS inhibitors/MRAs. Routine clinical visits every 3-6 months once stable.
Preventive Strategies
Screen first-degree relatives of patients with idiopathic or familial DCM with clinical exam, ECG, and echocardiography. Avoid excessive alcohol consumption and cardiotoxic medications if possible.
Prognosis has dramatically improved with modern GDMT. The 5-year survival rate is now around 70-80%. Patients showing reverse remodeling (improvement in LVEF) on medical therapy have excellent long-term survival. Prognosis is worse if LVEF remains <20%.